Vaccine resources
The Common Health Coalition is bringing together payers, providers, health systems, and public health leaders to prepare for and respond to the 2025-2026 respiratory virus season. Our goal: a coordinated response that better serves patients and communities. All resources below are free to use and indicate the date they were last updated. More will be added as the situation evolves.
Vaccine status update
Find the latest guidance and practice information on COVID-19, flu, and RSV vaccines.
Flu and RSV
Flu and RSV vaccine recommendations and access are straightforward and remain similar to last year. Medical specialty societies and the CDC recommend flu vaccination for everyone 6 months and older. RSV vaccinations are recommended for older adults, pregnant people, and infants.
Health leaders should encourage immunization, and patients should speak with their health care provider if they have questions. See recommendations from the June 2025 ACIP meeting and medical specialty societies linked below.
COVID-19
Recommendations: COVID-19 vaccines are safe, effective, and recommended. ACIP has not yet provided guidance on COVID-19 vaccines for the 2025-2026 season, but medical specialty societies have. See here for the American Academy of Pediatrics (AAP’s) updated immunization schedule and here for American College of Obstetricians and Gynecologists (ACOG’s) maternal immunization guidance. Additional medical specialty society recommendations are forthcoming.
FDA labels: On August 27, 2025, the FDA approved 2025-2026 COVID-19 vaccines with indications only for adults 65 and older and people 6 months to 64 years old with conditions that put them at high risk for severe illness. Read our full explainer.
- Pfizer (Comirnaty): Approved for use in individuals who are 65 years of age and older, or 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
- Moderna (Spikevax): Approved for use in individuals who are 65 years of age and older, or 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
- Novavax (Nuvaxovid): Approved for use in individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
Respiratory season vaccine planning toolkits
Download tailored toolkits for payers, providers, and state leaders to support coordinated vaccine planning and access.
Resources to guide payer vaccine coverage decisions and communications.
Tools to help providers integrate vaccine guidance into practice and patient communications.
Guidance for states to align on vaccine distribution and outreach.
Recommendations
Medical specialty societies publish evidence-based recommendations for vaccines each year. These recommendations help guide the public’s decision-making, clinical practice, payer coverage decisions, and health system purchasing.
If a specialty society has not yet released 2025-2026 guidance, its 2024-2025 recommendations remain applicable until updated.
Pediatrics
Pregnancy
Vaccine Integrity Project
The Vaccine Integrity Project (VIP) is an independent group of vaccine experts formed in response to federal vaccine policy changes. They met on August 19, 2025, to review the latest evidence on COVID-19, flu, and RSV vaccine effectiveness and safety. The executive summary of that meeting can be found here, and a recording can be found here.
Resources from the Coalition
Operational timeline for respiratory vaccines
Summarizes the prior years’ process to operationalize this season’s flu, RSV, and COVID-19 vaccines.
Respiratory virus coverage analysis
Outlines the current coverage landscape for commercial payers, government payers, and certain programs for COVID-19 flu vaccines and RSV immunizations.
ACIP and CDC vaccine recommendation updates
Summarizes changes to immunization recommendations across key populations made during the April and June 2025 ACIP meetings and revised guidance from the CDC on COVID-19 vaccines in May 2025.
Vaccine Injury Compensation Program notes
Outlines how changes to ACIP recommendations may impact federal vaccine injury compensation programs for flu and COVID-19 vaccines and RSV immunizations, focusing on coverage, liability protections, and regulatory processes.
Provider liability, coverage, and scope: Scenario tables
Helps providers, policymakers, and payers understand the implications of policy decisions linked to FDA labeling and ACIP recommendations.
Vaccines for Children Program overview
Summarizes the Vaccines for Children Program and answers common questions.
Respiratory season vaccine FAQs
Helps health care and public health leaders navigate uncertainty during the 2025-2026 respiratory virus season.
High-risk criteria for COVID-19
Compares how various health agencies define high-risk criteria for severe COVID-19 illness.
Regulatory briefs
Coverage and administration of COVID-19 vaccine for pregnant people
Summarizes current policies and recent changes to the coverage and administration of the COVID-19 vaccine for pregnant people.
Shared clinical decision-making recommendation: COVID-19 vaccine for children and youth
Summarizes how the CDC recommendation for “shared clinical decision-making” for the COVID-19 vaccine for children and youth affects coverage and administration of the vaccine (issued May 2025).
Coverage and administration of flu vaccines with thimerosal
Summarizes how flu vaccine coverage and administration will be largely unaffected by ACIP’s recommendation to prohibit thimerosal in vaccines.
Resources from partners
VaccineResourceHub.org
The nation’s largest hub for vaccine communications designed for community-based organizations, with content in over 50 languages.
Immunize.org
Hundreds of free immunization education materials for health care providers and patients.
Infodemiology.com
Insights into trending vaccine narratives designed for health care providers and public health professionals.
The Evidence Collective
Focused, actionable briefs that synthesize critical vaccine information.